{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:48:11Z","timestamp":1788871691711,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["23617018"],"award-info":[{"award-number":["23617018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.diabres.2012.01.024","type":"journal-article","created":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T06:19:49Z","timestamp":1329113989000},"page":"91-98","source":"Crossref","is-referenced-by-count":13,"title":["Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria"],"prefix":"10.1016","volume":"97","author":[{"given":"Shinya","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koka","family":"Motoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Wakikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeichi","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Emoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2012.01.024_bib0005","first-page":"S11","article-title":"Standards of medical care in diabetes\u20142011","volume":"34","year":"2011","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.diabres.2012.01.024_bib0010","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1161\/hh1901.097126","article-title":"Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels","volume":"89","author":"Hansen","year":"2001","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.diabres.2012.01.024_bib0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000210396","article-title":"Different effects of L\/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR\/Izm","volume":"30","author":"Konda","year":"2009","journal-title":"Am J Nephrol"},{"issue":"10","key":"10.1016\/j.diabres.2012.01.024_bib0020","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1097\/HJH.0b013e32833d01dd","article-title":"A new-generation N\/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker","volume":"28","author":"Konoshita","year":"2010","journal-title":"J Hypertens"},{"issue":"3","key":"10.1016\/j.diabres.2012.01.024_bib0025","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/10641960902822492","article-title":"Cilnidipine inhibits the sympathetic nerve activity and improves baroreflex sensitivity in patients with hypertension","volume":"31","author":"Kishi","year":"2009","journal-title":"Clin Exp Hypertens"},{"issue":"8","key":"10.1016\/j.diabres.2012.01.024_bib0030","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/10641960500298558","article-title":"Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine","volume":"27","author":"Tsuchihashi","year":"2005","journal-title":"Clin Exp Hypertens"},{"issue":"6","key":"10.1016\/j.diabres.2012.01.024_bib0035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1291\/hypres.27.379","article-title":"Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases","volume":"27","author":"Kojima","year":"2004","journal-title":"Hypertens Res"},{"issue":"12","key":"10.1016\/j.diabres.2012.01.024_bib0040","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.ki.5002623","article-title":"Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease","volume":"72","author":"Fujita","year":"2007","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.diabres.2012.01.024_bib0045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jdiacomp.2006.06.001","article-title":"Renoprotective effect of N-type Ca channel blockade in diabetic nephropathy","volume":"21","author":"Fujisawa","year":"2007","journal-title":"J Diabetes Complicat"},{"issue":"1","key":"10.1016\/j.diabres.2012.01.024_bib0050","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.ki.5000349","article-title":"Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria","volume":"70","author":"Katayama","year":"2006","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.diabres.2012.01.024_bib0055","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/147323001003800222","article-title":"The L\/N-type calcium channel blocker Cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes","volume":"38","author":"Tanaka","year":"2010","journal-title":"J Int Med Res"},{"issue":"6","key":"10.1016\/j.diabres.2012.01.024_bib0060","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.diabres.2012.01.024_bib0065","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0168-8227(01)00365-5","article-title":"Report of the Committee on the classification and diagnostic criteria of diabetes mellitus","volume":"55","author":"Kuzuya","year":"2002","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.diabres.2012.01.024_bib0070","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/ki.2008.49","article-title":"Antiproteinuric effects of cilnidipine","volume":"73","author":"Staessen","year":"2008","journal-title":"Kidney Int"},{"issue":"Suppl","key":"10.1016\/j.diabres.2012.01.024_bib0075","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1291\/hypres.29.S1","article-title":"Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004)","volume":"29","year":"2006","journal-title":"Hypertens Res"},{"key":"10.1016\/j.diabres.2012.01.024_bib0080","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1046\/j.1523-1755.1998.06704.x","article-title":"Heterogeneous activation mechanisms in the renal microvasculature","volume":"67","author":"Navar","year":"1998","journal-title":"Kidney Int Suppl"},{"issue":"10","key":"10.1016\/j.diabres.2012.01.024_bib0085","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1097\/HJH.0b013e3282c2fa62","article-title":"Renal and vascular protective effects of cilnidipine in patients with essential hypertension","volume":"25","author":"Morimoto","year":"2007","journal-title":"J Hypertens"},{"issue":"9","key":"10.1016\/j.diabres.2012.01.024_bib0090","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.diabres.2012.01.024_bib0095","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"3","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.diabres.2012.01.024_bib0100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MNH.0b013e3282f29028","article-title":"Aldosterone and progression of renal disease","volume":"17","author":"Wenzel","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"10.1016\/j.diabres.2012.01.024_bib0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/hr.2010.191","article-title":"Expression of N-type calcium channels in human adrenocortical cells and their contribution to corticosteroid synthesis","volume":"34","author":"Aritomi","year":"2011","journal-title":"Hypertens Res"},{"issue":"5","key":"10.1016\/j.diabres.2012.01.024_bib0110","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/00004872-200205000-00035","article-title":"N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME\/SHR model","volume":"20","author":"Zhou","year":"2002","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.diabres.2012.01.024_bib0115","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/HJH.0b013e328336ade3","article-title":"Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte","volume":"28","author":"Fan","year":"2010","journal-title":"J Hypertens"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822712000460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822712000460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,28]],"date-time":"2021-12-28T20:15:53Z","timestamp":1640722553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822712000460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0168822712000460"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2012.01.024","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}